cycloserine has been researched along with Hearing Loss in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Davis, JG; Farley, J; Lancaster, J; Odendaal, R; Shean, K; Van der Walt, M | 1 |
| Bharti, H; Bhushan, B; Chander, R; Gupta, A; Kajal, NC; Ranga, V | 1 |
| Adebola, SO; Adedeji, TO; Adefuye, BO; Oladeji, SM; Sogebi, OA | 1 |
3 other study(ies) available for cycloserine and Hearing Loss
| Article | Year |
|---|---|
Serious treatment related adverse drug reactions amongst anti-retroviral naïve MDR-TB patients.
Topics: Adult; Antitubercular Agents; Coinfection; Cycloserine; Drug Resistance, Multiple, Bacterial; Female; Hearing Loss; HIV Infections; Humans; Isoxazoles; Male; Middle Aged; Mycobacterium tuberculosis; Ofloxacin; Oxazolidinones; Prospective Studies; Psychoses, Substance-Induced; South Africa; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary | 2013 |
Profile of adverse drug reactions in drug resistant tuberculosis from Punjab.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Arthralgia; Ataxia; Chemical and Drug Induced Liver Injury; Child; Cycloserine; Drug Eruptions; Drug Therapy, Combination; Ethambutol; Ethionamide; Female; Gastrointestinal Diseases; Hearing Loss; Humans; Hypothyroidism; India; Kanamycin; Levofloxacin; Male; Middle Aged; Peripheral Nervous System Diseases; Psychoses, Substance-Induced; Pyrazinamide; Severity of Illness Index; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Vision Disorders; Young Adult | 2014 |
Clinical predictors of aminoglycoside-induced ototoxicity in drug-resistant Tuberculosis patients on intensive therapy.
Topics: Adult; Age Factors; Aminoglycosides; Antitubercular Agents; Audiometry, Pure-Tone; Body Mass Index; Coinfection; Comorbidity; Cycloserine; Diabetes Mellitus; Female; Hearing Loss; HIV Infections; Humans; Kanamycin; Levofloxacin; Male; Middle Aged; Nigeria; Prospective Studies; Prothionamide; Pyrazinamide; Risk Factors; Time Factors; Tuberculosis, Multidrug-Resistant; Young Adult | 2017 |